Salim Hayek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7266966/publications.pdf Version: 2024-02-01



SALIM HAVER

#	Article	IF	CITATIONS
1	Assay-related differences in SuPAR levels: implications for measurement and data interpretation. Journal of Nephrology, 2023, 36, 157-159.	0.9	3
2	Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin. Kidney International Reports, 2022, 7, 68-77.	0.4	10
3	Differences in Inflammation, Treatment, and Outcomes Between Black and Non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study. American Journal of Medicine, 2022, 135, 360-368.	0.6	5
4	Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. American Journal of Kidney Diseases, 2022, 79, 404-416.e1.	2.1	23
5	Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Clinical Infectious Diseases, 2022, 75, e623-e629.	2.9	20
6	Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Annals of the Rheumatic Diseases, 2022, 81, 875-880.	0.5	38
7	Molecular consequences of SARS-CoV-2 liver tropism. Nature Metabolism, 2022, 4, 310-319.	5.1	98
8	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR00000000000001063.	1.6	756
9	The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 417-425.	2.3	2
10	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
11	Increased incidence of immune-mediated myocarditis in advanced skin malignancies treated with immune checkpoint inhibitors in the COVID-19 era Journal of Clinical Oncology, 2022, 40, 2664-2664.	0.8	Ο
12	Association Between Early Treatment With Tocilizumab and Mortality Among Critically III Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 41.	2.6	385
13	AKI Treated with Renal Replacement Therapy in Critically III Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2021, 32, 161-176.	3.0	207
14	Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. Journal of Thrombosis and Thrombolysis, 2021, 51, 854-869.	1.0	20
15	New perspectives in cardio-oncology. Journal of Thrombosis and Thrombolysis, 2021, 51, 835-836.	1.0	Ο
16	Exposure and risk factors for COVID-19 and the impact of staying home on Michigan residents. PLoS ONE, 2021, 16, e0246447.	1.1	13
17	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. Intensive Care Medicine, 2021, 47, 208-221.	3.9	143
18	d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e500-e511.	0.4	35

#	Article	IF	CITATIONS
19	Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease 2019–Related Respiratory Failure*. Critical Care Medicine, 2021, 49, 1026-1037.	0.4	64
20	Questioning the Futility of Cardiopulmonary Resuscitation in Patients With Severe Coronavirus Disease 2019. Critical Care Medicine, 2021, 49, e795-e796.	0.4	1
21	A Systematic Review of the Incidence and Outcomes of In-Hospital Cardiac Arrests in Patients With Coronavirus Disease 2019*. Critical Care Medicine, 2021, 49, 901-911.	0.4	11
22	Management of Patients With Giant Cell Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1122-1134.	1.2	59
23	Application of regularized regression to identify novel predictors of mortality in a cohort of hemodialysis patients. Scientific Reports, 2021, 11, 9287.	1.6	0
24	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically III Patients With COVID-19. Annals of Internal Medicine, 2021, 174, 622-632.	2.0	89
25	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329.	3.0	64
26	Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. Journal of Clinical Medicine, 2021, 10, 3907.	1.0	17
27	Hospital-Level Variation in Death for Critically III Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 403-411.	2.5	39
28	Incidence, Predictors, and Outcomes of Inâ€Hospital Cardiac Arrest in COVIDâ€19 Patients Admitted to Intensive and Nonâ€Intensive Care Units: Insights From the AHA COVIDâ€19 CVD Registry. Journal of the American Heart Association, 2021, 10, e021204.	1.6	15
29	Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019. , 2021, 3, e0515.		12
30	Obesity, inflammatory and thrombotic markers, and major clinical outcomes in critically ill patients with COVIDâ€19 in the US. Obesity, 2021, 29, 1719-1730.	1.5	11
31	Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry. Cardio-Oncology, 2021, 7, 28.	0.8	7
32	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Circulation, 2021, 144, 1521-1523.	1.6	44
33	Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, CIR0000000000001032.	1.6	13
34	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients. Transplant International, 2021, 35, 10071.	0.8	2
35	Angiotensin onverting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVIDâ€19. Journal of the American Heart Association, 2021, 10, e023535.	1.6	15
36	Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 465-470.	0.4	12

#	Article	IF	CITATIONS
37	Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI. Journal of the American Society of Nephrology: JASN, 2020, 31, 2725-2735.	3.0	93
38	In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ, The, 2020, 371, m3513.	3.0	108
39	Ethnic differences in subclinical vascular function in South Asians, Whites, and African Americans in the United States. IJC Heart and Vasculature, 2020, 30, 100598.	0.6	2
40	Factors Associated With Death in Critically III Patients With Coronavirus Disease 2019 in the US. JAMA Internal Medicine, 2020, 180, 1436.	2.6	711
41	Chimeric Antigen Receptor T-Cell Therapy–Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation, 2020, 142, 1687-1690.	1.6	70
42	Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. American Journal of Transplantation, 2020, 20, 3061-3071.	2.6	89
43	COVID-19 and Diabetes: A Collision and Collusion of Two Diseases. Diabetes, 2020, 69, 2549-2565.	0.3	91
44	Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease. PLoS ONE, 2020, 15, e0237579.	1.1	18
45	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. Trends in Cardiovascular Medicine, 2020, 30, 315-325.	2.3	44
46	Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy. Journal of Cardiovascular Translational Research, 2020, 13, 417-430.	1.1	1
47	Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients. Frontiers in Cell and Developmental Biology, 2020, 8, 339.	1.8	15
48	Sex Differences in Circulating Soluble Urokinaseâ€Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease. Journal of the American Heart Association, 2020, 9, e015457.	1.6	16
49	Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis PatientsÂUndergoing TAVR. JACC: Cardiovascular Interventions, 2020, 13, 567-579.	1.1	16
50	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	13.9	149
51	Soluble urokinase plasminogen activator receptorÂ(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Critical Care, 2020, 24, 187.	2.5	140
52	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, , 1-10.	2.3	22
53	Metastatic melanoma of the heart: A systematic review Journal of Clinical Oncology, 2020, 38, e22017-e22017.	0.8	1
54	Implementation of Cardio-Oncology Training for Cardiology Fellows. JACC: CardioOncology, 2020, 2, 795-799.	1.7	6

Salim Hayek

#	Article	IF	CITATIONS
55	How to Say Goodbye. Journal of the American College of Cardiology, 2019, 74, 154-156.	1.2	1
56	Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer. Cardiology Clinics, 2019, 37, 505-523.	0.9	13
57	Low Educational Attainment is a Predictor of Adverse Outcomes in Patients With Coronary Artery Disease. Journal of the American Heart Association, 2019, 8, e013165.	1.6	28
58	Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2019, 30, 1305-1313.	3.0	23
59	Preparing the Cardiovascular Workforce to Care for Oncology Patients. Journal of the American College of Cardiology, 2019, 73, 2226-2235.	1.2	56
60	Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 2019, 5, 1.	0.8	54
61	Carcinoid Heart Disease. Cardiology Clinics, 2019, 37, 497-503.	0.9	10
62	Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart. Journal of the American College of Cardiology, 2019, 74, 3153-3163.	1.2	78
63	Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation. International Journal of Cardiology, 2019, 276, 255-260.	0.8	5
64	Outcomes From Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis and Left Ventricular Ejection Fraction Less Than 30%. JAMA Cardiology, 2019, 4, 64.	3.0	63
65	Sleep Duration and Mortality in Patients With Coronary Artery Disease. American Journal of Cardiology, 2019, 123, 874-881.	0.7	16
66	uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. Journal of Clinical Investigation, 2019, 129, 1946-1959.	3.9	48
67	High‣ensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Longâ€Term Outcomes. Journal of the American Heart Association, 2018, 7, .	1.6	57
68	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation Research, 2018, 122, 1565-1575.	2.0	35
69	Mean Aortic pressure gradient and global longitudinal strain recovery after transcatheter aortic valve replacement – A retrospective analysis. Hellenic Journal of Cardiology, 2018, 59, 268-271.	0.4	9
70	Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‧ensitivity Câ€Reactive Protein. Journal of the American Heart Association, 2018, 7, .	1.6	18
71	Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 1461-1466.	0.7	11
72	Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 1297-1308.	1.2	152

#	Article	IF	CITATIONS
73	Ibrutinib-Associated Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 1491-1500.	1.3	134
74	Cardio-Oncology for GenNext. Journal of the American College of Cardiology, 2018, 71, 2977-2981.	1.2	20
75	Circulating Progenitor Cells and Racial Differences. Circulation Research, 2018, 123, 467-476.	2.0	18
76	Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1013-1021.	2.2	23
77	Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study. Journal of Neuroinflammation, 2018, 15, 17.	3.1	108
78	Depression and chest pain in patients with coronary artery disease. International Journal of Cardiology, 2017, 230, 420-426.	0.8	37
79	Flow cytometric data analysis of circulating progenitor cell stability. Data in Brief, 2017, 10, 346-348.	0.5	11
80	Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. Kidney International Reports, 2017, 2, 425-432.	0.4	23
81	Paravalvular Regurgitation after Transcatheter Aortic Valve Replacement: Comparing Transthoracic versus Transesophageal Echocardiographic Guidance. Journal of the American Society of Echocardiography, 2017, 30, 533-540.	1.2	36
82	Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1265-1273.	2.2	23
83	Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	21
84	Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nature Medicine, 2017, 23, 100-106.	15.2	121
85	Changes in truncal obesity and fat distribution predict arterial health. Journal of Clinical Lipidology, 2017, 11, 1354-1360.e3.	0.6	20
86	Sex Differences in Circulating Progenitor Cells. Journal of the American Heart Association, 2017, 6, .	1.6	31
87	Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatrics, 2017, 171, e172914.	3.3	46
88	Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis, 2017, 264, 108-114.	0.4	27
89	Association between oxidative stress and atrial fibrillation. Heart Rhythm, 2017, 14, 1849-1855.	0.3	90
90	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	40

#	Article	IF	CITATIONS
91	A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nature Medicine, 2017, 23, 945-953.	15.2	176
92	Is it Time to Find a Role for Uric Acid Levels in the Prevention and Management of Hypertension. American Journal of Hypertension, 2017, 30, 16-18.	1.0	2
93	Bioactive Lipids and Circulating Progenitor Cells in Patients with Cardiovascular Disease. Stem Cells Translational Medicine, 2017, 6, 731-735.	1.6	4
94	Marital Status and Outcomes in Patients With Cardiovascular Disease. Journal of the American Heart Association, 2017, 6, .	1.6	54
95	Cohort profile: the Emory Cardiovascular Biobank (EmCAB). BMJ Open, 2017, 7, e018753.	0.8	26
96	2017 Roadmap for Innovation—ACCÂHealth Policy Statement on Healthcare Transformation in the EraÂof Digital Health, Big Data, andÂPrecision Health. Journal of the American College of Cardiology, 2017, 70, 2696-2718.	1.2	96
97	Effective Information Extraction Framework for Heterogeneous Clinical Reports Using Online Machine Learning and Controlled Vocabularies. JMIR Medical Informatics, 2017, 5, e12.	1.3	21
98	Variant <i>ASGR1</i> Associated with a Reduced Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 374, 2131-2141.	13.9	137
99	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. Nature Genetics, 2016, 48, 634-639.	9.4	214
100	Age and Human Regenerative Capacity Impact of Cardiovascular Risk Factors. Circulation Research, 2016, 119, 801-809.	2.0	46
101	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction Study (WISE-CVD). Atherosclerosis, 2016, 253, 111-117.	0.4	11
102	Anatomic Patterns of Renal Arterial Sympathetic Innervation: New Aspects for Renal Denervation. Journal of Interventional Cardiology, 2016, 29, 594-600.	0.5	20
103	Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 577-585.	1.2	74
104	Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol. Journal of Clinical Hypertension, 2016, 18, 223-231.	1.0	9
105	Effects of a Healthâ€Partner Intervention on Cardiovascular Risk. Journal of the American Heart Association, 2016, 5, .	1.6	16
106	Platelets confound the measurement of extracellular miRNA in archived plasma. Scientific Reports, 2016, 6, 32651.	1.6	84
107	Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease. Circulation Research, 2016, 119, 564-571.	2.0	42
108	Soluble Urokinase Receptor and Chronic Kidney Disease. New England Journal of Medicine, 2016, 374, 890-891.	13.9	16

#	Article	IF	CITATIONS
109	Psychosocial Risk Factors Related to Ischemic Heart Disease in Women. Current Pharmaceutical Design, 2016, 22, 3853-3870.	0.9	8
110	Effects of storageâ€ a ged red blood cell transfusions on endothelial function in hospitalized patients. Transfusion, 2015, 55, 782-790.	0.8	33
111	Response to Letters Regarding Article, "Infective Endocarditis After Transcatheter Aortic Valve Implantation: Results From a Large Multicenter Registry― Circulation, 2015, 132, e372-4.	1.6	3
112	Effect of storageâ€aged red blood cell transfusions on endothelial function in healthy subjects. Transfusion, 2015, 55, 2768-2770.	0.8	6
113	Low testosterone in men predicts impaired arterial elasticity and microvascular function. International Journal of Cardiology, 2015, 194, 94-99.	0.8	42
114	Echocardiographic and clinical factors related to paravalvular leak incidence in low-gradient severe aortic stenosis patients post-transcatheter aortic valve implantation. European Heart Journal Cardiovascular Imaging, 2015, 16, 558-563.	0.5	5
115	Tumor necrosis factor-alpha antagonism with etanercept improves endothelial progenitor cell counts in patients with psoriasis. International Journal of Cardiology, 2015, 182, 387-389.	0.8	10
116	Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation, 2015, 131, 1566-1574.	1.6	227
117	Provoking Coronary Vasospasm for Diagnosis of Variant Angina. JACC: Cardiovascular Interventions, 2015, 8, 924-926.	1.1	2
118	Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. Journal of the American Society of Hypertension, 2015, 9, 206-213.	2.3	16
119	Contribution of endothelium-derived hyperpolarizing factor to exercise-induced vasodilation in health and hypercholesterolemia. Vascular Medicine, 2015, 20, 14-22.	0.8	20
120	Soluble Urokinase Receptor and Chronic Kidney Disease. New England Journal of Medicine, 2015, 373, 1916-1925.	13.9	338
121	Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording. Circulation, 2015, 131, 469-477.	1.6	86
122	Dobutamine Stress Echocardiography for RiskÂStratification of Patients With Low-Gradient Severe Aortic Stenosis Undergoing TAVR. JACC: Cardiovascular Imaging, 2015, 8, 380-382.	2.3	23
123	A randomised controlled doubleâ€blind clinical trial of 17â€hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (<scp>PROGESTWIN</scp>): evidence for reduced neonatal morbidity. BJOG: an International Journal of Obstetrics and Gynaecology, 2015, 122, 71-79.	1.1	33
124	The role of cardiovascular magnetic resonance in stratifying paravalvular leak severity after transcatheter aortic valve replacement: an observationalÂoutcome study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 93.	1.6	58
125	Differences in Vascular Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor Bioavailability in Blacks and Whites. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1320-1327.	1.1	50
126	Echocardiographic Assessment of Pulmonary Artery Systolic Pressure and Outcomes in Ambulatory Heart Failure Patients. Journal of the American Heart Association, 2014, 3, e000363.	1.6	33

#	Article	IF	CITATIONS
127	Transcatheter valve-in-valve implantation for degenerated mitral valve bioprosthesis under 3D echocardiographic guidance. Expert Review of Cardiovascular Therapy, 2014, 12, 1035-1036.	0.6	3
128	Assessment of Right Ventricular Function in Left Ventricular Assist Device Candidates. Circulation: Cardiovascular Imaging, 2014, 7, 379-389.	1.3	83
129	Endothelium-Derived Hyperpolarizing Factor Mediates Bradykinin-Stimulated Tissue Plasminogen Activator Release in Humans. Journal of Vascular Research, 2014, 51, 200-208.	0.6	12
130	Cardiac Magnetic Resonance for Paravalvular Leaks in Post-Transcatheter Aortic Valve Replacement. Circulation, 2014, 129, e430-1.	1.6	15
131	DOBUTAMINE STRESS ECHOCARDIOGRAPHY RISK-STRATIFIES WOMEN WITH LOW-GRADIENT AORTIC STENOSIS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT. Journal of the American College of Cardiology, 2014, 63, A1975.	1.2	0
132	End-of-Life Care Planning: Improving Documentation of Advance Directives in the Outpatient Clinic Using Electronic Medical Records. Journal of Palliative Medicine, 2014, 17, 1348-1352.	0.6	31
133	Incidence and clinical characteristics of takotsubo cardiomyopathy post-aneurysmal subarachnoid hemorrhage. International Journal of Cardiology, 2014, 176, 1362-1364.	0.8	49
134	Digging Deep: High Output Heart Failure in Renal Cell Carcinoma. American Journal of Medicine, 2014, 127, 22-24.	0.6	3
135	Multiparametric Assessment of Post-Transcatheter Aortic Valve Repacement Paravalvular Regurgitation Grading by Transthoracic Echocardiography and Cardiac Magnetic Resonance. Journal of Clinical & Experimental Cardiology, 2014, 05, .	0.0	0
136	Transcatheter valve-in-valve implantation for a degenerated mitral valve bioprosthesis under echocardiographic guidance. Hellenic Journal of Cardiology, 2014, 55, 338-41.	0.4	1
137	Prevalence of Resistant Hypertension and Eligibility for Catheter-Based Renal Denervation in Hypertensive Outpatients. American Journal of Hypertension, 2013, 26, 1452-1458.	1.0	32
138	Effect of Progenitor Cell Mobilization With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Peripheral Artery Disease. JAMA - Journal of the American Medical Association, 2013, 310, 2631.	3.8	33
139	Rare Elizabethkingia meningosepticum meningitis case in an immunocompetent adult. Emerging Microbes and Infections, 2013, 2, 1-4.	3.0	12
140	Paravalvular Aortic Leak After Transcatheter Aortic Valve Replacement. Circulation, 2013, 127, 397-407.	1.6	183
141	Antiretroviral Therapy–associated Coccidioidal Meningitis. Emerging Infectious Diseases, 2013, 19, 163-165.	2.0	13
142	Cardiac Natriuretic Peptides: From Basic Discovery to Clinical Practice. Cardiovascular Therapeutics, 2011, 29, 362-376.	1.1	50
143	ZFP260 Is an Inducer of Cardiac Hypertrophy and a Nuclear Mediator of Endothelin-1 Signaling. Journal of Biological Chemistry, 2011, 286, 1508-1516.	1.6	11
144	Shoulder Dystocia: What is the Risk of Recurrence?. Obstetrical and Gynecological Survey, 2009, 64, 143-144.	0.2	0

#	Article	IF	CITATIONS
145	Shoulder dystocia: What is the risk of recurrence?. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 992-997.	1.3	16